Back to top
more

Exelixis (EXEL)

(Real Time Quote from BATS)

$36.82 USD

36.82
110,340

-0.44 (-1.18%)

Updated Aug 4, 2025 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

by Zacks Equity Research

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

by Zacks Equity Research

Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.

Ekta Bagri headshot

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

Kinjel Shah headshot

Merck to End Development of Two Cancer Candidates: Time to Sell?

by Kinjel Shah

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Zacks Equity Research

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

by Zacks Equity Research

Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.

Zacks Equity Research

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%

by Zacks Equity Research

LLY's board approves a new $15B stock buyback plan and announces a 15% increase in its quarterly dividend.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

EXEL or INCY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. INCY: Which Stock Is the Better Value Option?

Zacks Equity Research

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

by Zacks Equity Research

FDA grants priority review to AZN's sBLA seeking expanded use of Imfinzi for muscle-invasive bladder cancer.

Zacks Equity Research

Acadia (ACAD) Down 2.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JHSC

Zacks Equity Research

Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JHSC

Zacks Equity Research

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

by Zacks Equity Research

The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.

Zacks Equity Research

Zacks Investment Ideas feature highlights: InterDigital, Futu and Exelixis

by Zacks Equity Research

InterDigital, Futu and Exelixis have been highlighted in this Investment Ideas article.

Ethan Feller headshot

End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)

by Ethan Feller

InterDigital, Futu Holdings and Exelixis are all stocks with reasonable valuations and bullish catalysts